Sign in

Sana Al Sukhun

@sanaalsukhun.bsky.social
16 followers 43 following 8 posts

#Cancer & blood doctor in Jordan; Focus on #breast cancer #health for all #women empowerment- equity not equality- #global oncology #precision oncology- posts are my own

PostsRepliesMedia
Sana Al Sukhun @sanaalsukhun.bsky.social · 08/02/2025
Really enjoyed joining Emirates Oncology Society @bestofSABCS & the interesting discussion. Congrats @aydah-alawadhi.bsky.social & @humaidalshamsi.bsky.social on excellent organization; great line of speakers & great hospitality @sabcs.bsky.social @ecancer.org @oncodaily.bsky.social #bcsm #brca
120
Sana Al Sukhun @sanaalsukhun.bsky.social · 26/01/2025
Had a great time @ #17thBGIICC, and #Oncothoracic int. congress Ontic; sharing ideas during my talk; connecting with so many brilliant colleagues. Huge thanks and congrats to @Hesham ElGhazaly and team for hosting such a fantastic event. @hoperugo.bsky.social @jrgralow.bsky.social #Oncology #bcsm
020
Sana Al Sukhun @sanaalsukhun.bsky.social · 24/12/2024
Best wishes for a Merry Christmas and a peaceful, healthy, happy new year to all. May 2025 usher in an era of human tolerance; peace and health for all
media.tenor.com
a merry christmas eve greeting card with a christmas tree
ALT: a merry christmas eve greeting card with a christmas tree
000
Sana Al Sukhun @sanaalsukhun.bsky.social · 13/12/2024
Thoughtful discussion of #ZEST trial & #ctDNA by Dr Krop in early #Breastcancer - bottom line NOT IN CLINIC YET ⁦‪@SABCSSanAntonio‬⁩ #SABCS2024 @oncodaily.bsky.social @oncodaily.bsky.social
020
Sana Al Sukhun @sanaalsukhun.bsky.social · 12/12/2024
Results from the #NRG Oncology/RTOG 9804 and #ECOG-ACRIN E5194 Trial for Good risk #DCIS INDEED reinforced the role of #RT to reduce ITR since Tam benefit was limited to ipsilat IR _ #RTx more tolerable than 5yrs of #Tamoxifen @sabcs.bsky.social @oncoalert.bsky.social @oncodaily.bsky.social
021
Sana Al Sukhun @sanaalsukhun.bsky.social · 12/12/2024
@prat_aleix discusses promising #Asian data especially from @Fudanuni @Shanghai cancer centre with #antibody drug conjugate SHR-A1811 demonstrating non-inferiority to the standard quadruple therapy in early #BreastCancer #CancerResearch @sabcs.bsky.social @oncodaily.bsky.social
010
Sana Al Sukhun @sanaalsukhun.bsky.social · 12/12/2024
Oral SERD #Imlunestrant in #EMBER3 is shifting the game! No need to check for ESR1 mutations when combined with #verzenio, as revealed by @breastcancerdoc.bsky.social at @sabcs.bsky.social Insightful discussion by @DrBurstein #BreastCancer #OncologyBreakthroughs www.nejm.org/doi/full/10....
nejm.org
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer | NEJM
Imlunestrant is a next-generation, brain-penetrant, oral selective estrogen-receptor (ER) degrader that delivers continuous ER inhibition, even in cancers with mutations in the gene encoding ERα (E...
0101